Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2016 by Taylor & Francis Group, LLC. The human body and in particular the human immune system have evolved a large number of mechanisms to control viral infections. Multiple mechanical and immunological barriers exist that inhibit and restrict viral entry, infections as well as replication. A first barrier is the surface of the body, which usually does not allow penetration by viral particles and blocks viral infection from the very start. If viruses successfully overcome this first barrier, a number of innate sensing mechanisms exist in practically every cell type (e.g., RIG-I, Mda5, LGP2, STING, AIM2 [Imaizumi et al. 2002; Gitlin et al. 2006; Ishikawa et al. 2009; Schmidt et al. 2009; Satoh et al. 2010; Barber 2011]). These intracellular molecules sense viral infection, causing the production of type I IFN, which globally inhibits viral replication by inducing degradation of viral nucleic acids or inhibition of viral replication (Bowie and Unterholzner 2008; Yan and Chen 2012). Plasmacytoid dendritic cells (pDCs) of the innate immune system have evolved a particularly powerful sensing system for viral infection and are the dominant producers of antiviral type I interferon (Colonna et al. 2004; McKenna et al. 2005). In addition to recognition of viral nucleic acids, both the innate and adaptive immune systems have evolved various ways to recognize and inactivate exogenous viral particles as well as infected cells (Zinkernagel 1996). Both arms of the immune system collaborate to achieve maximal specific immune responses.

Original publication

DOI

10.1201/b18596

Type

Chapter

Book title

Viral Nanotechnology

Publication Date

01/01/2015

Pages

121 - 128